solitomab
{{Drugbox
| type = mab
| image =
| alt =
| mab_type = BiTE
| source = o
| target = EpCAM
| tradename =
| Drugs.com =
| MedlinePlus =
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category=
| legal_AU =
| legal_CA =
| legal_UK =
| legal_US =
| legal_status =
| routes_of_administration =
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
| CAS_number = 1005198-65-1
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = ZQQ51B5708
| ATC_prefix = none
| ATC_suffix =
| PubChem =
| DrugBank =
| ChemSpiderID = none
| chemical_formula =
| molecular_weight =
}}
Solitomab (INN; development code MT110) is an artificial bispecific monoclonal antibody that is being investigated as an anti-cancer drug. It is a fusion protein consisting of two single-chain variable fragments (scFvs) of different antibodies on a single peptide chain of about 55 kilodaltons. One of the scFvs binds to T cells via the CD3 receptor, and the other to EpCAM as a tumor antigen against gastrointestinal, lung, and other cancers.{{cite journal |journal=Oncology NEWS International |volume=17 |issue=6 |date= June 2008 |first=Caroline |last=Helwick | name-list-style = vanc |url=http://www.cancernetwork.com/display/article/10165/1165525|title=Novel BiTE antibody mediates contact between T cells and cancer cells}}{{ClinicalTrialsGov|NCT00635596|Phase I Study of MT110 in Colorectal Cancer (CRC), Gastrointestinal (GI) and Lung Cancer (MT110-101)}}{{cite journal | vauthors = Amann M, D'Argouges S, Lorenczewski G, Brischwein K, Kischel R, Lutterbuese R, Mangold S, Rau D, Volkland J, Pflanz S, Raum T, Münz M, Kufer P, Schlereth B, Baeuerle PA, Friedrich M | display-authors = 6 | title = Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release | journal = Journal of Immunotherapy | volume = 32 | issue = 5 | pages = 452–64 | date = June 2009 | pmid = 19609237 | doi = 10.1097/CJI.0b013e3181a1c097 | s2cid = 25568468 }}
Mechanism of action
File:BiTE antibody en.svg to a tumor cell.]]
Like other bispecific antibodies, and unlike ordinary monoclonal antibodies, solitumab forms a link between T cells and its target tumor cell antigen. This causes T cells to exert cytotoxic activity on tumor cells by producing proteins like perforin and granzymes, independently of the presence of MHC I or co-stimulatory molecules. These proteins enter tumor cells and initiate the cell's apoptosis.{{cite web|url=http://www.micromet.de/index.php?id=67|title=BiTE Antibody Platform|publisher=Micromet Inc}} This action mimics physiological processes observed during T cell attacks against tumor cells.